Q2040
Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- 2021 Status Change: Discontinue procedure or modifier code
- Effective Date: 2018-01-01
- Termination Date: 2018-12-31
- Medicare Coverage Status: Carrier Judgement
- BETOS Classification: Other drugs
Medicare has not assigned a fee schedule for this code
Q2039
Q2041 